Continuous dopamine-receptor stimulation in advanced Parkinson's disease
- PMID: 11052228
- DOI: 10.1016/s1471-1931(00)00029-x
Continuous dopamine-receptor stimulation in advanced Parkinson's disease
Abstract
Intermittent or pulsatile dopamine-receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of the motor fluctuations and dyskinesia that complicate long-term L-dopa therapy of Parkinson's disease. As a corollary to this hypothesis, continuous dopamine-receptor stimulation can avoid or reverse these complications. Such continuous stimulation is unlikely to mimic completely the normal function of the dopaminergic system, but should avoid the supra-physiological swings in extracellular dopamine that accompany intermittent L-dopa dosing. The concern is that this continuous stimulation might induce tolerance rather than sensitization to some effects of L-dopa. Open clinical trials support the value of continuous dopaminergic stimulation in Parkinson's disease with established motor complications, but rigorous studies, although experimentally difficult, are needed.
Similar articles
-
Continuous dopamine-receptor stimulation in early Parkinson's disease.Trends Neurosci. 2000 Oct;23(10 Suppl):S117-26. doi: 10.1016/s1471-1931(00)00030-6. Trends Neurosci. 2000. PMID: 11052229 Review.
-
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x. Eur J Neurol. 2011. PMID: 21255197 Review.
-
An approach to the continuous dopaminergic stimulation in Parkinson's disease.Isr Med Assoc J. 2012 Mar;14(3):175-9. Isr Med Assoc J. 2012. PMID: 22675859 Review.
-
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.Curr Opin Neurol. 2003 Dec;16 Suppl 1:S3-7. doi: 10.1097/00019052-200312001-00002. Curr Opin Neurol. 2003. PMID: 15180131 Review.
-
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924. Clin Neuropharmacol. 2010. PMID: 20414107 Review.
Cited by
-
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.Pharmacoeconomics. 2001;19(10):1013-38. doi: 10.2165/00019053-200119100-00004. Pharmacoeconomics. 2001. PMID: 11735671 Review.
-
Future of cell and gene therapies for Parkinson's disease.Ann Neurol. 2008 Dec;64 Suppl 2(0 2):S122-38. doi: 10.1002/ana.21473. Ann Neurol. 2008. PMID: 19127583 Free PMC article.
-
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.Curr Neuropharmacol. 2016;14(4):356-63. doi: 10.2174/1570159x14666151208114634. Curr Neuropharmacol. 2016. PMID: 26644151 Free PMC article. Review.
-
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.Eur J Neurosci. 2012 Sep;36(6):2839-48. doi: 10.1111/j.1460-9568.2012.08202.x. Epub 2012 Jul 5. Eur J Neurosci. 2012. PMID: 22762478 Free PMC article.
-
Acute levodopa dosing around-the-clock ameliorates REM sleep without atonia in hemiparkinsonian rats.NPJ Parkinsons Dis. 2019 Nov 29;5:27. doi: 10.1038/s41531-019-0096-2. eCollection 2019. NPJ Parkinsons Dis. 2019. PMID: 31815176 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials